Baseimmune launches IPF pipeline using computational multi-pathway antigen design. Preclinical readouts due 2026-27. Discover what this means for fibrosis drug development.
Curatis and Neupharma sign a CHF 83.5m Japan licensing deal for corticorelin in peritumoral brain edema. Read our analysis of what the deal means.
ESTEVE acquires Prialt and Quzyttir from TerSera Therapeutics. Discover what this deal signals for non-opioid pain drugs and hospital specialty medicines.
TETON-2 phase 3 data show nebulized treprostinil slows IPF lung decline and cuts clinical worsening risk. Analysis of what the NEJM results mean.
Pretzel Therapeutics advances PX578 for POLG disease. Discover how mitochondrial DNA restoration could reshape treatment for rare mitochondrial disorders.
BridgeBio Pharma reports Phase 3 BBP-418 results and prepares FDA filing. Could this become the first therapy for limb-girdle muscular dystrophy?
PolTREG advances its TREG cell therapy for type 1 diabetes toward EU approval. Learn what this milestone means for autoimmune disease treatment.
TIXiMED reports preclinical data showing oral TIX100 may prevent weight regain after GLP-1 therapy. Discover what this could mean for obesity treatment.
Oragenics begins Phase IIa testing of ONP-002 for concussion. Discover how this trial could reshape drug development for traumatic brain injury.
Rademikibart Phase 3 eczema data will debut at AAD 2026. Discover what the trial could mean for IL-4 receptor biologics and global dermatology drug competition.